d'Ancona Gráinne, Kent Brian D
Guy's and St Thomas' NHS Foundation Trust, London, UK.
School of Pharmaceutical Sciences, King's College London, London, UK.
Breathe (Sheff). 2024 Dec 10;20(3):240001. doi: 10.1183/20734735.0001-2024. eCollection 2024 Oct.
Inhaled therapies, primarily the inhaled corticosteroid (ICS), have been the cornerstone of asthma treatment since the 1960s. They have been shown to reduce symptom burden, morbidity and mortality, and potentially avoid unnecessary and unscheduled healthcare. However, some people have severe asthma, defined by an inability to gain or maintain consistent disease control despite appropriate use of high dose ICS-containing inhalers. In this review, we discuss whether it is appropriate to demand adherence to a treatment this cohort are demonstrably resistant to.
自20世纪60年代以来，吸入疗法，主要是吸入性糖皮质激素（ICS），一直是哮喘治疗的基石。已证明它们可减轻症状负担、发病率和死亡率，并有可能避免不必要的非计划性医疗保健。然而，有些人患有严重哮喘，其定义为尽管适当使用了含高剂量ICS的吸入器，但仍无法获得或维持持续的疾病控制。在本综述中，我们讨论了要求这一明显对某种治疗有抗性的人群坚持该治疗是否合适。
